SEC For	rm 4																
FORM 4 UNITED STA) STAT	ES S			ES AND ington, D.C. 2		NGE C	OMMIS	SSION		OMB	APPRO\	/AL	
Section 16. Form 4 or Form 5 obligations may continue. See					NT OF CHANGES IN BENEFICIAL OWNERSHIP d pursuant to Section 16(a) of the Securities Exchange Act of 1934									OMB Number: 3235-0287 Estimated average burden hours per response: 0.5			
1. Name and Address of Reporting Person* Shah Gauray					or Section 30(h) of the Investment Company Act of 1940 2. Issuer Name and Ticker or Trading Symbol ROCKET PHARMACEUTICALS, INC. RCKT							ck all applica	able)	10% Owner			
(Last) (First) (Middle) C/O ROCKET PHARMACEUTICALS, INC. 9 CEDARBROOK DRIVE													Officer (give title Other (specify below) below) CEO				
(Street) CRANBURY NJ 08512					4. If Amendment, Date of Original Filed (Month/Day/Year)							Individual or Joint/Group Filing (Check Applicable ie) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	itate)	(Zip)														
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transa Date (Month/C)						ar) 3. 3. Transaction Code (Instr. 8) 4. Securi Disposed		ities Acquired (A) or d Of (D) (Instr. 3, 4 and		5. Amoun Securities Beneficia Owned Fo Reported	s lly ollowing	Form	Direct I Indirect I str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								Code V	Amount	(A) o (D)	r Price	Transacti (Instr. 3 a	on(s) Ind 4)				
								luired, Dis s, options				Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/\	Coc	nsaction le (Instr.			6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Cod	le V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	(Instr. 4)		511(5)			
Stock Option (Right to Buy)	\$20.04	02/14/2023		А		348,590		(1)	02/13/2033	Common Stock	348,590	\$0	348,59	90	D		
Restricted Stock	(2)	02/14/2023		А		116,317		(3)	(3)	Common Stock	116,317	\$0	116,31	17	D		

Explanation of Responses:

Stock Units

1. This option represents a right to purchase a total of 348,590 shares of the Issuer's common stock, one-third (1/3) of which will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years.

2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

3. One-third (1/3) of such restricted stock units will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years.

/s/ Martin Wilson, as attorney-	02/16/2023			
in-fact for Gaurav Shah	02/16/2023			
** Signature of Reporting Person	Date			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.